Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
AssigneeGenmedica Therapeutics Sl
InventorsLuc Marti Clauzel, Silvia Garcia Vicente, Francesc Yraola Font, Miriam Royo Exposito, Fernando Albericio Palomera, Antonio Zorzano Olarte
Life of this patent
Estimating the term…
Abstract
This invention is directed to inhibitors of copper-containing amine oxidases (E.C.1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-I), and their therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer.
Claims68
1-42. (canceled)
A compound of formula:
- R3—(Y)n—(CR2R2)m-Z
- or a pharmaceutically acceptable salt thereof, wherein
- m is 1-4;
- n is 1;
- Z is CONR10H;
- Y is —C(O)NH—;
- R1 is independently H or C1-C6 alkyl;
- R2 is independently H or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with OH, NH2, or SH;
- and
- R3 is aryl selected from phenyl, naphthyl, indanyl, and biphenyl, C5-C6 cycloalkyl, heteroaryl
- selected from pyridyl, pyrimidyl, indolyl, pyrrolyl, thienyl, furanyl, thiazolyl, pyrazolyl,
- and oxazolyl, heterocycloalkyl selected from piperazinyl, piperidinyl, pyrrolidinyl,
- quinolinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, and
- S,S-dioxothiomorpholinyl, each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently C1-C6 alkyl, C1-C6 alkoxy, halogen, CF3, OCF3, nitro, CN, CO2H, C1-C6 alkylthio, C1-C6 acyloxy, phenyl, pyridyl, thienyl, furanyl, pyrimidyl, or hydroxy.
A compound of formula
- wherein
- R10 and R20 are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, substituted aryl, heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl or C1-C6 alkoxy, aryl or substituted aryl;
- R30 and R40 are independently H, OH, SH, halogen, nitro, amino, mono or di(C1-C6 alkyl)amino, C1-C6 alkyl, C1-C6 alkanoyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where the cyclic portion, the alkyl portion or a combination thereof of each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, substituted aryl, halogen, nitro, nitroso, aldehyde, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, mono or di(C1-C6 alkyl)amino, C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl or nitrile;
- Y1 is (CH2), or aryl;
- m is 0, 1, 2, 3, or 4;
- n is 0, 1, 2, 3, or 4;
- W is NHOH, NH2, NHR10, OR10, or NH—NHR10;
- X1 and X2 are independently C, CH, or N, provided that X1 and X2 are not simultaneously N;
- where the dashed lines represent a cycloalkyl or aryl group that is optionally present;
- and
- n and m independently an integer from 1 to 5.
A compound of formula
- wherein
- n is an integer from 1 to 5;
- R10 is independently H, C1-C6 alkyl, aryl, C2-C6 alkenyl, C2-C6alkynyl, substituted aryl, heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, or substituted aryl;
- R20 is H, C1-C6 alkyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, arylalkoxy, substituted aryl, halogen, nitro, nitroso, aldehyde, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl or nitrile;
- or
- R10, R20 and the carbon to which they are attached form a cycloalkyl ring;
- R40 is H, C1-C6 alkyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, arylalkoxy, substituted aryl, halogen, nitro, nitroso, aldehyde, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl or nitrile;
- or
- Y1 is SO2, C(O), CH2, or —NHC(O);
- and
- W is NHOH, NHR10, OR10, or NH—NHR10.
A compound of formula
- wherein
- n is an integer from 1 to 5;
- R10 is independently H, C1-C6 alkyl, aryl, C2-C6 alkenyl, C2-C6alkynyl, substituted aryl,
- heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or
- C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl or C1-C6 alkoxy, aryl or substituted aryl;
- R20 is independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, substituted aryl, heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl or C1-C6 alkoxy, aryl or substituted aryl;
- R30 is independently H, C1-C6 alkyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, substituted aryl, halogen, nitro, nitroso, aldehyde, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl or nitrile;
- or
- R20, R30, and the carbon to which they are attached form a cycloalkyl ring;
- or
- optionally encompasses olefins when n is 2-5, in such a case, R20 is not present on the olefinic carbons.
- R40 is H, C1-C6 alkyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, substituted aryl, halogen, nitro, nitroso, aldehyde, carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl or nitrile;
- Y1 is CH2, C(O), or SO2;
- and
- W at each occurrence is independently NHOH, NHR10, OR10, or NH—NHR10.
A compound of formula
- wherein
- R20 and R30 are independently H, C1-C6 alkyl, aryl, substituted aryl, heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, OH, SH, C1-C6 alkyl or C1-C6 alkoxy, aryl, or substituted aryl;
- W is NHOH, NHR10, OR10, or NH—NHR10;
- X is C, CH, or any heteroatom selected from S, N, and O;
- Y1 is CO, or CH2;
- and
- the dashed lines represent an optional aryl, heteroaryl or heterocycloalkyl ring.
A compound of formula
- wherein
- R10 and R20 are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, substituted aryl, heterocycloalkyl containing one or two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl, or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl or C1-C6 alkoxy, aryl or substituted aryl.
A compound of formula
- wherein
- R20 is —CH2—X, —CH2CH2—X, —CH(CH3)—X, —CH2CH2CH2—X, —CH2CH2CH2CH2—X or —CH2CH2—O—X;
- and
- X is phenyl or naphthyl optionally substituted with 1 or 2 groups selected from methoxy, —F, or —OH.
The compound N-hydroxy-2-(2-(2-methyl-1H-indol-3-yl)acetamido)acetamide.
The compound N-hydroxy-4-({[(4-methylphenyl)sulfonyl]amino}methyl)benzamide.
The compound N-(1H-indol-2-ylcarbonyl)glutamic acid.
The compound 1-(isoquinolin-1-ylcarbonyl)prolinamide.
The compound 5-amino-2-hydroxy-N-(2-phenoxyethyl)benzamide.
The compound selected from
- N2-(biphenyl-4-ylsulfonyl)-N1-hydroxythreoninamide;
- 3-amino-N2-(biphenyl-4-ylsulfonyl)-N1-hydroxyalaninamide;
- N1-hydroxy-N2-[(4-propylphenyl)sulfonyl]serinamide;
- N1-hydroxy-N2-[(4-propylphenyl)sulfonyl]threoninamide;
- N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N1-hydroxyserinamide;
- N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N1-hydroxythreoninamide;
- N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N1-hydroxyglycinamide;
- N1-hydroxy-N2-(2-naphthylsulfonyl)serinamide;
- N1-hydroxy-N2-(2-naphthylsulfonyl)threoninamide;
- N1-hydroxy-N2-[(4-methyl-3-nitrophenyl)sulfonyl]serinamide;
- N1-hydroxy-N2-(2-naphthylsulfonyl)glycinamide;
- N1-hydroxy-N2-[(4-methylphenyl)sulfonyl]threoninamide;
- 3-amino-N1-hydroxy-N2-[(4-methylphenyl)sulfonyl]alaninamide;
- N1-hydroxy-N2-(quinolin-7-ylsulfonyl)threoninamide;
- N2-{[8-(dimethylamino)-2-naphthyl]sulfonyl}-N1-hydroxyserinamide;
- and
- N2-{[8-(dimethylamino)-2-naphthyl]sulfonyl}-N1-hydroxythreoninamide.
A method of treating an animal having a disease or disorder characterized by pathological expression of a copper-containing amine oxidase enzyme, comprising administering to an animal in need of such treatment an inhibitor of said copper-containing amine oxidase at a therapeutically-active concentration, wherein the inhibitor is a compound of formula
- R3—(Y)n—(CR2R2)m-Z
- or a pharmaceutically acceptable salt thereof, wherein
- m is 0 or 1-6;
- n is 0 or 1;
- Z is CONR10H, COOH, B(OH)2, SO2NR1OH, OR1, SR1, NHR1, PO3H, CH2NHR1, COR1, CONHR1, CHNR1, or CNR1NHR1;
- Y at each occurrence is independently —CO—, —CS—, —NR2OR2—, —NR2—, —SR2—, —NR2SO2R2—, —COR2—, —NR2—C(NR2)—NR2—, —(C1-C6 alkyl)-NHC(O)—, —(C1-C6 alkyl)-N(C1-C6 alkyl)C(O)—, —NHC(O)—(C1-C6 alkyl)-, —N(C1-C6 alkyl)C(O)—(C1-C6 alkyl)-, —NHC(O)—, —N(C1-C6alkyl)C(O)—, —C(O)NH—, —C(O)—N(C1-C6alkyl), —SO2NH—, —SO2—N(C1-C6alkyl)-, —(C1-C6 alkyl)-C(O)NH—, —(C1-C6 alkyl)-C(O)—N(C1-C6alkyl)-, —O—(C1-C6 alkyl)-NHC(O)—, or —O—(C1-C6 alkyl)-N(C1-C6 alkyl)C(O)—, wherein the alkyl portion or portions of each of the above is optionally substituted with 1, 2, or 3 groups that are independently halogen, C1-C4 alkoxy, amino, mono or di (C1-C6 alkyl)amino, OH, indolyl, pyrrolyl, pyridyl, furanyl, guanidinyl, carboxyl, or ═O;
- R1 at each occurrence is independently H, C1-C6 alkyl, aryl, substituted aryl, heterocycloalkyl containing at least one and no more than two heteroatoms selected from S, N, and O, or C3-C7 cycloalkyl, and where any member of the alkyl, aryl/or cycloalkyl group is optionally substituted with halogen, C1-C6 alkyl or C1-C6 alkoxy, aryl or substituted aryl;
- R2 at each occurrence is independently H, C1-C6 alkyl, carboxyl, C1-C6 alkoxycarbonyl, aryl, substituted aryl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 cycloalkylalkoxy, heteroaryl, heteroarylalkyl, heterocycloalkyl, or heterocycloalkylalkyl, where each of the above is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C6 alkyl, C1-C6 alkoxy, aryl, substituted aryl, halogen, nitro, nitroso, aldehyde (CHO), carboxylic acid, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)(C1-C6 alkyl), amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)(C1-C6 alkyl), C1-C6 alkoxycarbonyl, sulfate, imine, hydroxyl, —SH, or nitrile;
- and R3 is aryl, C1-C6 alkyl, C2-C4 alkenyl, C3-C7 cycloalkyl, C3-C7 cycloalkyl C1-C6 alkyl, C3-C7 cycloalkyl C1-C6 alkoxy, heteroaryl, heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently C1-C6 alkyl, C1-C6 alkoxy, halogen, haloalkyl, haloalkoxy, nitro, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)(C1-C6 alkyl), CN, CO2H, C1-C6 alkylthio, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C6 acyloxy, aryl, heteroaryl, or hydroxyl, where the aryl and heteroaryl substituents on R3 are further optionally substituted with one or more groups that are independently C1-C6 alkyl, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)(C1-C6 alkyl), OH, NO2, C1-C6 alkoxy, halogen, arylalkoxy (in one aspect, phenylalkoxy, in another aspect, phenylCl alkoxy), haloalkyl (in one aspect, CF3), haloalkoxy (in one aspect, OCF3), thiol, or C2-C6 alkanoyl (in one aspect, C2 alkanoyl);
- at a therapeutically-active concentration.
A pharmaceutical composition comprising a compound, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient, diluent or adjuvant thereof, wherein the compound is selected from:
- N-hydroxy-2-(2-(2-methyl-1H-indol-3-yl)acetamido)acetamide;
- N-hydroxy-4-({[(4-methylphenyl)sulfonyl]amino}methyl)benzamide;
- N-(1H-indol-2-ylcarbonyl)glutamic acid;
- 1-(isoquinolin-1-ylcarbonyl)prolinamide;
- 5-amino-2-hydroxy-N-(2-phenoxyethyl)benzamide;
- N2-(biphenyl-4-ylsulfonyl)-N1-hydroxythreoninamide;
- 3-amino-N2-(biphenyl-4-ylsulfonyl)-N1-hydroxyalaninamide;
- N1-hydroxy-N2-[(4-propylphenyl)sulfonyl]serinamide;
- N1-hydroxy-N2-[(4-propylphenyl)sulfonyl]threoninamide;
- N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N1-hydroxyserinamide;
- N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N-hydroxythreoninamide;
- N2-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-N1-hydroxyglycinamide;
- N1-hydroxy-N2-(2-naphthylsulfonyl)serinamide;
- N1-hydroxy-N2-(2-naphthylsulfonyl)threoninamide;
- N1-hydroxy-N2-[(4-methyl-3-nitrophenyl)sulfonyl]serinamide;
- N1-hydroxy-N2-(2-naphthylsulfonyl)glycinamide;
- N1-hydroxy-N2-[(4-methylphenyl)sulfonyl]threoninamide;
- 3-amino-hydroxy-N2-[(4-methylphenyl)sulfonyl]alaninamide;
- N1-hydroxy-N2-(quinolin-7-yl sulfonyl)threoninamide;
- N2-{[8-(dimethylamino)-2-naphthyl]sulfonyl}-N1-hydroxyserinamide;
- and
- N2-{[8-(dimethylamino)-2-naphthyl]sulfonyl}-N1-hydroxythreoninamide.
Dependencies are inferred from the claim text.